HOME >> MEDICINE >> NEWS
Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Tibotec Therapeutics announces initiation of the largest U.S. clinical study examining HIV treatment in treatment-experienced adult women

GRACE trial to explore gender-related differences in response to PREZISTA-based HIV therapy

Bridgewater, NJ, [Thursday, September 28, 2006] -- Tibotec Therapeutics Clinical Affairs, a division of Ortho Biotech Clinical Affairs, LLC, announced today the initiation of the largest clinical study conducted to date in treatment-experienced adult women with HIV to evaluate gender differences in response to an HIV medication.

GRACE (Gender, Race And Clinical Experience), a multi-center, open-label Phase IIIb trial, will compare gender differences in the efficacy, safety and tolerability of PREZISTA (darunavir) tablets administered with other antiretroviral agents over a 48-week treatment period. The study also will explore racial differences in treatment outcomes.

PREZISTA, co-administered with 100 mg ritonavir (PREZISTA/rtv) and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. PREZISTA received accelerated approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) studies. Longer-term data will be required before the FDA can consider traditional approval for PREZISTA (see the full indication and important safety information below).

There is an urgent need to conduct clinical trials designed specifically for women with HIV. The ratio of women to men among Americans diagnosed with HIV has grown substantially since the HIV epidemic first emerged.

Today, women account for almost 30 percent of new HIV diagnoses in the U.S., and rates of HIV infection are particularly high among
'"/>

Contact: Pamela Van Houten
908-541-4137
Edelman Public Relations
28-Sep-2006


Page: 1 2 3 4 5

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. GSK announces launch of largest ever Phase III trial in lung cancer treatment
5. Elsevier announces launch of Brain Stimulation
6. NSW Premier announces $15M for childrens cancer research
7. National Inventors Hall of Fame announces 2007 inductees
8. Emory University announces new Global Health Institute
9. BioMed Central announces Journal of Medical Case Reports
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Poor students get more fruits and vegetables at school than ... the opposite is true for students from wealthier families. ... may give a healthy boost to poor students, diets, according ... income level, students all ate a similar amount of fruits ... was published recently in the journal Preventive Medicine . ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... in America, and work commitment is a big reason why, ... killer," said Dr. Mathias Basner, an assistant professor of sleep ... School of Medicine. A time-use survey of nearly 125,000 ... the main activity exchanged for sleep. Short sleepers -- those ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s ... new study providing evidence on the impact of 100% ... , Sufficient enough evidence already exists showing a negative ... drinks, with the onset of tooth decay. One question ... as 100% fruit juice, meaning it is completely natural ...
(Date:12/15/2014)... Health Dialog, a leading provider of ... has received Patient Oriented Accreditation from the National ... Management (DM) Programs for asthma, congestive heart failure, ... and diabetes. This marks the 12th continuous year ... Management (DM) Programs, reaffirming Health Dialog’s focus and ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
Cached News: